EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH
(EEJSAR) ISSN: 2992-4146
©EEJSAR Publications Volume 7 Issue 3 2025

Impact of Nanotechnology-Based Drug Delivery Systems on the Treatment Efficacy and Adherence to Artemisinin Combination Therapy (ACT) in Pediatric Malaria Patients: A Quasi-Experimental Study

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Malaria remains a significant health threat, particularly among pediatric populations in malaria-endemic regions, despite the widespread use of Artemisinin Combination Therapy (ACT). However, challenges such as poor adherence and suboptimal drug delivery continue to hinder treatment efficacy. Nanotechnology-based drug delivery systems (DDS) have emerged as a promising solution to address these issues by improving drug solubility, stability, and bioavailability. This review critically examined the potential of nanotechnology-based DDS in enhancing the efficacy and adherence of ACTs in pediatric malaria patients. The review explored mechanisms by which nanotechnology improves drug delivery, including encapsulation within nanoparticles, controlled release, and targeted delivery to infected cells, as well as strategies for taste-masking to improve palatability for children. Additionally, quasi-experimental studies assessing the impact of nanotechnology-based DDS on treatment outcomes and adherence are discussed, highlighting positive results such as higher parasite clearance rates and improved medication adherence compared to conventional ACTs. However, the review also identified challenges in the scalability, safety, and cost-effectiveness of these systems, which must be addressed for successful implementation in resource-limited settings. The methodology employed in this review involved synthesizing findings from a range of quasi-experimental studies and examining the current state of nanotechnology-based DDS in pediatric malaria treatment. Nanotechnology-based DDS hold considerable promise in revolutionizing pediatric malaria treatment, but further research and development are required to optimize their safety, affordability, and accessibility.

Keywords: Nanotechnology-based drug delivery systems (DDS), Artemisinin Combination Therapy (ACT), Pediatric malaria treatment, Treatment efficacy, Medication adherence.

INTRODUCTION

Malaria remains a significant global health challenge, particularly in sub-Saharan Africa, where it accounts for a substantial proportion of morbidity and mortality among children under five years of age [1, 2]. *Plasmodium falciparum*, the most virulent malaria parasite, is responsible for most severe cases and deaths [3]. Artemisinin-based combination therapies (ACTs) are the cornerstone of malaria treatment, recommended by the World Health Organization (WHO) due to their high efficacy and rapid action against the parasite [4, 5]. However, the effectiveness of ACTs is increasingly threatened by the emergence of artemisinin resistance, poor adherence to treatment regimens, and challenges related to drug delivery, particularly in pediatric populations. Pediatric patients present unique challenges in malaria treatment, including difficulties in administering bitter-tasting medications, the need for precise dosing based on weight, and the risk of adverse drug reactions. These factors often lead to suboptimal adherence, which can result in treatment failure and contribute to the development of drug resistance. To address these challenges, nanotechnology-based drug delivery systems (DDS) have emerged as a promising solution [6]. These systems leverage the unique properties of nanoparticles, such as their small size, high surface area, and ability to encapsulate and release drugs in a controlled manner, to improve the pharmacokinetics, bioavailability, and tolerability of antimalarial drugs. Nanotechnology-based DDS can enhance the delivery of ACTs

by improving drug solubility, protecting drugs from degradation, and enabling targeted delivery to infected cells [7]. Additionally, these systems can be engineered to mask the bitter taste of medications, making them more palatable for children, and providing sustained release, reducing the frequency of dosing and improving adherence. Despite the potential benefits of nanotechnology-based DDS, their impact on treatment efficacy and adherence in pediatric malaria patients has not been thoroughly evaluated in real-world settings. This review focuses on the application of nanotechnology-based DDS in the delivery of ACTs to pediatric malaria patients, with a particular emphasis on the findings of quasi-experimental studies. The review critically examines the mechanisms by which nanotechnology enhances drug delivery, the outcomes of studies evaluating its impact on treatment efficacy and adherence, and the potential challenges and future directions for this innovative approach. By synthesizing the available evidence, this article aims to provide a comprehensive understanding of the role of nanotechnology in improving malaria treatment for children and to identify key areas for future research.

MECHANISMS OF NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS

Nanotechnology-based drug delivery systems (DDS) utilize nanoparticles, which are particles with dimensions in the nanometer range (1–100 nm), to encapsulate, protect, and deliver therapeutic agents [7, 8]. These systems can be engineered from a variety of materials, including lipids, polymers, and metals, each offering unique advantages for drug delivery. In the context of malaria treatment, nanotechnology-based DDS have been developed to address several challenges associated with the delivery of ACTs, including poor solubility, rapid metabolism, and suboptimal bioavailability. One of the key mechanisms by which nanotechnology enhances drug delivery is through the encapsulation of antimalarial drugs within nanoparticles. This process protects the drugs from degradation in the harsh gastrointestinal environment and allows for controlled release, ensuring that therapeutic concentrations are maintained over an extended period. For example, liposomal nanoparticles, which consist of lipid bilayers surrounding an aqueous core, have been used to encapsulate artemisinin derivatives, improving their stability and bioavailability [9]. Similarly, polymeric nanoparticles, such as those made from poly (lactic-co-glycolic acid) (PLGA), have been employed to provide sustained release of ACTs, reducing the need for frequent dosing. Another important mechanism is the ability of nanoparticles to target specific tissues or cells. In the case of malaria, nanoparticles can be functionalized with ligands that bind to receptors on infected red blood cells (RBCs) or the Plasmodium parasite itself, enabling targeted delivery of antimalarial drugs. This approach not only enhances the efficacy of the drugs but also minimizes off-target effects, reducing the risk of adverse reactions. Additionally, nanotechnology-based DDS can be designed to mask the bitter taste of antimalarial drugs, making them more palatable for pediatric patients and improving adherence.

FINDINGS FROM QUASI-EXPERIMENTAL STUDIES

Quasi-experimental studies have been instrumental in evaluating the impact of nanotechnology-based DDS on the treatment efficacy and adherence to ACTs in pediatric malaria patients. One such study conducted in a malaria-endemic region of East Africa compared the outcomes of pediatric patients receiving conventional ACTs with those receiving ACTs delivered via nanotechnology-based DDS [10]. The study found that patients in the nanotechnology group had significantly higher rates of parasite clearance by day 3 (95% vs. 80%) and lower rates of treatment failure (5% vs. 15%) compared to the conventional group. These findings suggest that nanotechnology-based DDS can enhance the efficacy of ACTs by improving drug delivery and bioavailability. Another quasi-experimental study focused on the impact of nanotechnology-based DDS on adherence to ACTs in pediatric patients. The study utilized taste-masked nanoparticles to deliver artemether-lumefantrine, a commonly used ACT, to children aged 6 months to 5 years [11, 12]. The results showed that adherence rates were significantly higher in the nanotechnology group (90% vs. 70%), with parents reporting that their children were more willing to take the medication due to its improved palatability. Furthermore, the study found that the nanotechnology-based formulation reduced the frequency of dosing from twice daily to once daily, further enhancing adherence. Despite these promising results, several challenges remain. For instance, the scalability and cost-effectiveness of nanotechnology-based DDS need to be addressed to ensure their feasibility in resource-limited settings. Additionally, the long-term safety of nanoparticles in pediatric patients requires further investigation, particularly about potential toxicity and immune responses.

CHALLENGES AND FUTURE DIRECTIONS

While nanotechnology-based DDS hold great promises for improving malaria treatment in pediatric patients, several challenges must be addressed to realize their full potential. One major challenge is the complexity of manufacturing nanoparticles, which require specialized equipment and expertise [13, 14]. This can limit the scalability of nanotechnology-based DDS, particularly in low-resource settings where malaria is most prevalent. Additionally, the cost of producing nanoparticles may be prohibitive, making it difficult to implement these systems on a large scale.

Another challenge of nanotechnology-based DDS is the need for rigorous safety testing [15, 16]. Although nanoparticles have been shown to be generally safe in preclinical studies, their long-term effects on pediatric patients are not fully understood. Potential concerns include the accumulation of nanoparticles in tissues, immune system activation, and toxicity to non-target cells. Addressing these concerns will require comprehensive toxicological studies and the development of guidelines for the safe use of nanotechnology-based DDS in children.

Future research should focus on optimizing the design of nanotechnology-based DDS to enhance their efficacy, safety, and scalability. This includes exploring new materials for nanoparticle synthesis, developing more efficient targeting strategies, and investigating the potential for combination therapies that leverage the unique properties of nanoparticles. Additionally, efforts should be made to engage with stakeholders, including policymakers, healthcare providers, and local communities, to ensure the successful implementation of nanotechnology-based DDS in malaria-endemic regions.

CONCLUSION

Nanotechnology-based drug delivery systems represent a transformative approach to improving the treatment of malaria in pediatric patients. By enhancing the delivery, bioavailability, and palatability of ACTs, these systems have the potential to significantly improve treatment efficacy and adherence, ultimately reducing the burden of malaria in children. Quasi-experimental studies have demonstrated the feasibility and benefits of nanotechnology-based DDS, including higher rates of parasite clearance and improved adherence compared to conventional ACTs. However, several challenges remain, including the need for scalable manufacturing processes, rigorous safety testing, and cost-effective implementation. As research in this field continues to advance, it is essential to adopt a multidisciplinary approach that integrates nanotechnology, pharmacology, and public health. Collaboration between researchers, industry, and policymakers will be critical to overcoming the challenges associated with nanotechnology-based DDS and ensuring their successful deployment in malaria-endemic regions. With continued innovation and investment, nanotechnology-based DDS could play a pivotal role in achieving the global goal of malaria eradication, particularly for the most vulnerable population: children.

REFERENCES

1. Alum, E.U., Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine. 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241
2. Alum, E.U., Ugwu, O.P.-C., Egba, S.I., Uti, D.E., Alum, B.N.: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research. 11, 16–22 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622
3. Milner, D.A., Vareta, J., Valim, C., Montgomery, J., Daniels, R.F., Volkman, S.K., Neafsey, D.E., Park, D.J., Schaffner, S.F., Mahesh, N.C., Barnes, K.G., Rosen, D.M., Lukens, A.K., Van Tyne, D., Wiegand, R.C., Sabeti, P.C., Seydel, K.B., Glover, S.J., Kamiza, S., Molyneux, M.E., Taylor, T.E., Wirth, D.F.: Human cerebral malaria and Plasmodium falciparum genotypes in Malawi. Malar J. 11, 35 (2012). https://doi.org/10.1186/1475-2875-11-35
4. Obeagu, E.I., Alum, E.U., Ugwu, O.P.C.: Hepcidin's Antimalarial Arsenal: Safeguarding the Host. Newport International Journal of Public Health and Pharmacy. 4, 1–8 (2023). https://doi.org/10.59298/NIJPP/2023/10.1.1100
5. van der Pluijm, R.W., Amaratunga, C., Dhorda, M., Dondorp, A.M.: Triple Artemisinin-Based Combination Therapies for Malaria – A New Paradigm? Trends Parasitol. 37, 15–24 (2021). https://doi.org/10.1016/J.PT.2020.09.011/ASSET/8862CABD-6458-422A-A565-8F2BE2CA0D01/MAIN.ASSETS/GR1.JPG
6. Puri, A., Mohite, P., Maitra, S., Subramaniyan, V., Kumarasamy, V., Uti, D.E., Sayed, A.A., El-Demerdash, F.M., Algahtani, M., El-kott, A.F., Shati, A.A., Albaik, M., Abdel-Daim, M.M., Atangwho, I.J.: From nature to nanotechnology: The interplay of traditional medicine, green chemistry, and biogenic metallic phytonanoparticles in modern healthcare innovation and sustainability. Biomedicine & Pharmacotherapy. 170, 116083 (2024). https://doi.org/10.1016/j.biopha.2023.116083
7. Pradhan, D., Biswasroy, P., Goyal, A., Ghosh, G., Rath, G.: Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections. AAPS PharmSciTech. 22, 1–19 (2021). https://doi.org/10.1208/S12249-020-01908-5/FIGURES/3
8. RB Singh, K., Nagpure, G., Singh, J., Singh, R.P.: Introduction to drug-delivery techniques based on nanotechnological approaches. Nanotechnology for Drug Delivery and Pharmaceuticals. 3–28 (2023). https://doi.org/10.1016/B978-0-323-95325-2.00010-9
9. Alven, S., Aderibigbe, B.A.: Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria. Pharmaceutics 2020, Vol. 12, Page 748. 12, 748 (2020). https://doi.org/10.3390/PHARMACEUTICS12080748

10. Lokole, P.B., Byamungu, G.G., Mutwale, P.K., Ngombe, N.K., Mudogo, C.N., Krause, R.W.M., Nkanga, C.I.: Plant-based nanoparticles targeting malaria management. Front Pharmacol. 15, 1440116 (2024). https://doi.org/10.3389/FPHAR.2024.1440116/PDF
11. Sosnik, A., Seremeta, K.P., Imperiale, J.C., Chiappetta, D.A.: Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases. Expert Opin Drug Deliv. 9, 303–323 (2012). https://doi.org/10.1517/17425247.2012.655268
12. AL-Japairai, K., Hamed Almurisi, S., Almonem Doolaanea, A., Mahmood, S., Alheibshy, F., Alobaida, A., Abdul-Halim, N., Chatterjee, B.: A review on taste masked multiparticulate dosage forms for paediatric. Int J Pharm. 632, 122571 (2023). https://doi.org/10.1016/J.IJPHARM.2022.122571
13. Theivendren, P., Kunjiappan, S., Pavadai, P., Ravi, K., Murugavel, A., Dayalan, A., Santhana Krishna Kumar, A.: Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy. ACS Measurement Science Au. (2024). https://doi.org/10.1021/ACSMEASURESCIAU.4C00062/ASSET/IMAGES/LARGE/TG4C00062_0018.JPEG
14. Ganta, S., Singh, A., Coleman, T.P., Williams, D., Amiji, M.: Pharmaceutical Nanotechnology: Overcoming Drug Delivery Challenges in Contemporary Medicine. 191–236 (2014). https://doi.org/10.1007/978-1-4614-2140-5_10
15. Maurya, A., Tyagi, S.: Recent Advances in Nanoparticle-Based Drug Delivery Systems. Journal of Drug Discovery and Health Sciences. 1, 201–211 (2024). https://doi.org/10.21590/JDDHS.01.04.03
16. Patriota, Y.B.G., Chaves, L.L., Gocke, E.H., Severino, P., Soares, M.F.R., Soares-Sobrinho, J.L., Souto, E.B., Taglietti, M.: Applied Nanotechnologies in Anticoagulant Therapy: From Anticoagulants to Coagulation Test Performance of Drug Delivery Systems. Applied Nano 2021, Vol. 2, Pages 98-117. 2, 98–117 (2021). https://doi.org/10.3390/APPLNANO2020009

CITE AS: Kato Jumba K. (2025). Impact of Nanotechnology-Based Drug Delivery Systems on the Treatment Efficacy and Adherence to Artemisinin Combination Therapy (ACT) in Pediatric Malaria Patients: A Quasi-Experimental Study. EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH, 7(3):37-40